LennardMS. Genetic polymorphism of sparteine/debrisoquin oxidation: a reappraisal. Pharmacol Toxicol1990; 67:273–83.
2.
Van AckerSA, KoymansL, Donne-Op den KeiderGM, te KoppleM, VermeidenNPE. Mapping the active site of cytochrome P450IIDl (abstract). Pharmaceut Weekblad1990; 12(suppl B):B9.
3.
TurgeonJ, EvansWE, RellingMV, WilkinsonGR, RodenDM. Phenotypic debrisoquin 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. Br J Clin Pharmacol1991; 32:283–8.
4.
BooblsAR, MurrayS, HampdenCE, DavlesDS. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquin 4-hydroxylase and bufuralol l'-hydroxylase activities. Biochem Pharmacol1985; 34:65–71.
5.
DayerP, LeemannT, StriberniR.Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db, activity. Clin Pharmacol Ther1989; 54:34–40.
6.
HaefeliWE, BargetziMJ, FollathF, MeyerUA. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. J Cardiovasc Pharmacol1990; 15:776–9.
7.
RellingMV, CherrieJ, SchellJ, PetrosWP, MeyerWH, EvansWE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther1991; 50:308–13.
8.
DesmeulesJ, DayerP, GasconM-P, MagistrisM.Impact of genetic and environmental factors on codeine analgesia (abstract). Clin Pharmacol Ther1989; 45:122.
9.
BrosenK.Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet1990; 18:220–39.
10.
AlvanG.Clinical consequences of polymorphic oxidation. Fundam Clin Pharmacol1991; 5:209–28.
11.
LewisRV, RamsayLE, JacksonPR, YeoWW, LennardMS, TuckerGT. Influence of debrisoquin oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects. Br J Clin Pharmacol1991; 31:391–8.
12.
LeeJT, KroemerHK, SilbersteinDJ, Funck-BrentanoC, LineberryMD, WoodAJJThe role of genetically determined polymorphic drug metabolism in die beta-blockade produced by propafenone. N Engl J Med1990; 322:1764–8.
13.
LennardMS, TuckerGT, WoodsHF. Inborn “errors” of drug metabolism: pharmacokinetics and clinical implications. Clin Pharmacokinet1990; 19:257–63.
14.
KupferA, PreisigR.Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol1984; 26:753–9.
15.
WedlundPJ, AslanianWS, McAllisterWS, WilkinsonGR, BranchRA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther1984; 36:773–80.
16.
BertilssonL, BaillieTA, ReviriegoJ.Factors influencing die metabolism of diazepam. Pharmacol Ther1990; 45:85–91.
17.
BertilssonL, HenthornTK, SanzE, TybringG, SaweJ, VillenT.Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther1989; 45:348–55.
18.
InabaT, JurimaM, MahonWA, KalowW.In vitro inhibition studies of two isozymes of human liver cytochrome P-450: mephenytoin hydroxylase and sparteine monooxygenase. Drug Metab Dispos1985; 13:443–8.
19.
KumanaCR, LauderIJ, ChanM, KoW, LinHJ. Differences in diazepam pharmacokinetics in Chinese and white Caucasians. Eur J Clin Pharmacol1987; 32:211–5.
20.
AnderssonT, RegardhCG, Dahl-PuustinenM-L, BertilssonL.Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit1990; 12:415–6.
21.
AnderssonT, CederbergC, EdvardssonG, HeggelundA, LundborgP.Effect of omeprazole on diazepam metabolism in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther1990; 47:79–85.
22.
WardSA, WalleT, WalleUK, WilkinsonGR, BranchRA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther1989; 45:72–9.
23.
HallSD, GuengerichFP, BranchRA, WilkinsonGR. Characterization and inhibition of mephenytoin hydroxylase activity in human liver microsomes. J Pharmacol Ther1987; 240:216–22.
24.
SkjelboE, BrosenK, HallasJ, GramLF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther1991; 49:18–23.
25.
BrosenK, OttonSV, GramLF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther1986; 40:543–9.
26.
HelsbyNA, WardSA, HowellsRE, BreckenridgeAM. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase enzyme. Br J Clin Pharmacol1990; 30:287–91.
27.
HelsbyNA, WardSA, EdwardsG, HowellsRE, BreckenridgeAM. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol1990; 30:593–8.
28.
WardSA, HelsbyNA, SkjelboE, BrosenK, BreckenridgeAM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism—a panel study. Br J Clin Pharmacol1991; 31:689–92.
29.
AtibaJO, BlaschkeTF, WilkinsonGR. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquin. Br J Clin Pharmacol Ther1989; 28:161–5.
30.
ZhouHH, AnthonyLD, WoodAJJ, WilkinsonGR. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol1990; 30:471–5.
31.
CombalbertJ, FabreI, FabreG, DaletI, DerancourtJ, CanoJPMetabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P-450IIIA gene subfamily. Drug Metab Disp1989; 17:197–207.
32.
PichardL, FabreI, FabreG, DomergueJ, AubertBS, MouradGCyclosporin A drug inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos1990; 18:595–606.
33.
BackDJ, TjiaJF. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol1991; 32:624–6.
34.
FritzS, LindnerW, RootsI, FreyBM, KupferA.Sterochemistry of aromatic DPH hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther1987; 241:615–22.
35.
SchellensJHM, Van der WartJHF, BreimerDD. Relationship between mephenytoin oxidation polymorphism and DPH, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects. Br J Clin Pharmacol1990; 29:665–71.
36.
DoeckeCJ, VeroneseME, PondSM, MinersJO, BirkettDJ, SansomLNRelationship between DPH and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol1991; 31:125–30.
37.
VeroneseME, MackenziePI, DoeckeCJ, McManusME, MinersJO, BirkettDJ. Tolbutamide and Phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun1991; 175:1112–8.
38.
RellingMV, AoyamaT, GonzalezFJ, MeyerUA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP-2C subfamily. J Pharmacol Exp Ther1990; 252:442–7.
39.
SrivastavaPK, YunC-H, BeaunePH, GedC, GuengerichFP. Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4'-hydroxylase cytochrome P-450 enzymes. Molec Biol1991; 40:69–79.
40.
LadonaMG, LindstromB, ThyrC, Dun-RenP, RaneA.Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol1991; 32:295–302.
